KR102293386B1 - 신규한 (시아노-디메틸-메틸)-이속사졸 및 -[1,3,4]티아디아졸 - Google Patents
신규한 (시아노-디메틸-메틸)-이속사졸 및 -[1,3,4]티아디아졸 Download PDFInfo
- Publication number
- KR102293386B1 KR102293386B1 KR1020157032851A KR20157032851A KR102293386B1 KR 102293386 B1 KR102293386 B1 KR 102293386B1 KR 1020157032851 A KR1020157032851 A KR 1020157032851A KR 20157032851 A KR20157032851 A KR 20157032851A KR 102293386 B1 KR102293386 B1 KR 102293386B1
- Authority
- KR
- South Korea
- Prior art keywords
- pain
- pharmaceutical composition
- composition according
- acid
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- YHBMRXRUKLRIQK-UHFFFAOYSA-N CC(C)(C(O)=O)N(C)C(CC1)CCN1S(C)(=O)=O Chemical compound CC(C)(C(O)=O)N(C)C(CC1)CCN1S(C)(=O)=O YHBMRXRUKLRIQK-UHFFFAOYSA-N 0.000 description 1
- HGGZUBKUDSEXBV-UHFFFAOYSA-N CC(C)(C)OC(NC(CC1)CCN1NC)=O Chemical compound CC(C)(C)OC(NC(CC1)CCN1NC)=O HGGZUBKUDSEXBV-UHFFFAOYSA-N 0.000 description 1
- BVSNHVUSSUREGZ-UHFFFAOYSA-N CC(C)(C)OC(NC(CC1)CCN1S(C)(=O)=O)=O Chemical compound CC(C)(C)OC(NC(CC1)CCN1S(C)(=O)=O)=O BVSNHVUSSUREGZ-UHFFFAOYSA-N 0.000 description 1
- PJTIDKZHWHXSFG-UHFFFAOYSA-N CCOC(C(C)(C)N(C)C(CC1)CCN1S(C)(=O)=O)=O Chemical compound CCOC(C(C)(C)N(C)C(CC1)CCN1S(C)(=O)=O)=O PJTIDKZHWHXSFG-UHFFFAOYSA-N 0.000 description 1
- VLPXIZTYRZONAU-UHFFFAOYSA-N CCOC(C(C)(C)NC(CC1)CCN1S(C)(=O)=O)=O Chemical compound CCOC(C(C)(C)NC(CC1)CCN1S(C)(=O)=O)=O VLPXIZTYRZONAU-UHFFFAOYSA-N 0.000 description 1
- FLQSRSQNICPZIH-UHFFFAOYSA-N CS(N(CC1)CCC1N)(=O)=O Chemical compound CS(N(CC1)CCC1N)(=O)=O FLQSRSQNICPZIH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13168165.2A EP2803668A1 (en) | 2013-05-17 | 2013-05-17 | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| EP13168165.2 | 2013-05-17 | ||
| PCT/EP2014/060033 WO2014184327A1 (en) | 2013-05-17 | 2014-05-16 | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160008191A KR20160008191A (ko) | 2016-01-21 |
| KR102293386B1 true KR102293386B1 (ko) | 2021-08-26 |
Family
ID=48428381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157032851A Active KR102293386B1 (ko) | 2013-05-17 | 2014-05-16 | 신규한 (시아노-디메틸-메틸)-이속사졸 및 -[1,3,4]티아디아졸 |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US8865744B1 (https=) |
| EP (2) | EP2803668A1 (https=) |
| JP (1) | JP6309616B2 (https=) |
| KR (1) | KR102293386B1 (https=) |
| CN (1) | CN105229000B (https=) |
| AR (1) | AR096338A1 (https=) |
| AU (1) | AU2014267197B2 (https=) |
| BR (1) | BR112015028235A2 (https=) |
| CA (1) | CA2912463C (https=) |
| CL (1) | CL2015003286A1 (https=) |
| DK (1) | DK2997027T3 (https=) |
| EA (1) | EA031021B1 (https=) |
| ES (1) | ES2626396T3 (https=) |
| IL (1) | IL242309B (https=) |
| MX (1) | MX350885B (https=) |
| NZ (1) | NZ713614A (https=) |
| PH (1) | PH12015502523A1 (https=) |
| PL (1) | PL2997027T3 (https=) |
| PT (1) | PT2997027T (https=) |
| TW (1) | TW201536762A (https=) |
| UA (1) | UA118031C2 (https=) |
| UY (1) | UY35571A (https=) |
| WO (1) | WO2014184327A1 (https=) |
| ZA (1) | ZA201507957B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| SMT201900223T1 (it) | 2013-05-17 | 2019-07-11 | Incyte Corp | Sale di bipirazolo come inibitore di jak |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CA3049389A1 (en) * | 2017-01-06 | 2018-07-12 | Clexio Biosciences Ltd. | Topical detomidine formulations |
| IL311485B1 (en) | 2018-02-16 | 2026-01-01 | Incyte Corp | JAK1 pathway inhibitors for the treatment of cytokine-related disorders |
| MD3773593T2 (ro) | 2018-03-30 | 2024-10-31 | Incyte Corp | Tratament hidradenitei supurative utilizând inhibitori ai JAK |
| FI4157831T3 (fi) | 2020-06-02 | 2024-12-02 | Incyte Corp | Menetelmiä jak1-estäjän valmistamiseksi |
| WO2022125670A1 (en) | 2020-12-08 | 2022-06-16 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of vitiligo |
| RS67455B1 (sr) | 2021-05-03 | 2025-12-31 | Incyte Corp | Inhibitori jak1 puta za lečenje prurigo nodularisa |
Family Cites Families (145)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3116284A (en) | 1963-12-31 | Chs chj | ||
| US3117128A (en) | 1964-01-07 | Certificate of correction | ||
| CH312963A (de) | 1953-03-10 | 1956-03-15 | Sandoz Ag | Verfahren zur Herstellung von Azofarbstoffen |
| GB853799A (en) | 1957-11-21 | 1960-11-09 | Pfizer & Co C | Diquaternary compounds and process of preparing same |
| GB884258A (en) | 1958-11-06 | 1961-12-13 | Ciba Ltd | A new quinone derivative |
| GB1237126A (en) | 1968-04-10 | 1971-06-30 | Agfa Gevaert Nv | 3-acyl-amino-pyrazolin-5-ones |
| US3577462A (en) | 1968-08-08 | 1971-05-04 | American Home Prod | N-arylalkyl-beta-hydroxy-beta-phenyl-ethylamines and the salts thereof |
| US3966809A (en) | 1973-11-19 | 1976-06-29 | Stauffer Chemical Company | Insect repellent compounds |
| US4257954A (en) | 1978-08-08 | 1981-03-24 | Sterling Drug Inc. | Novel compounds, processes and marking systems |
| US4672065A (en) | 1982-11-19 | 1987-06-09 | Chevron Research Company | N-substituted phenoxyacetamide fungicides |
| US4535087A (en) | 1982-11-19 | 1985-08-13 | Chevron Research Company | N-Substituted phenoxyacetamide fungicides |
| US4859707A (en) | 1983-08-23 | 1989-08-22 | Key Pharmaceuticals, Inc. | Sulfur-substituted phenylacetamides |
| JPS6127955A (ja) | 1984-07-18 | 1986-02-07 | Hokko Chem Ind Co Ltd | アリ−ルスルホニル脂肪酸アミド誘導体、その製造法および除草剤 |
| JPS6127905A (ja) | 1984-07-18 | 1986-02-07 | Hokko Chem Ind Co Ltd | 除草剤 |
| JPS6127905U (ja) | 1984-07-25 | 1986-02-19 | 本田技研工業株式会社 | Ｏｈｃ型内燃機関 |
| JPS61126071A (ja) | 1984-11-22 | 1986-06-13 | Hokko Chem Ind Co Ltd | 農園芸用殺菌剤 |
| DE3600950A1 (de) | 1986-01-15 | 1987-07-16 | Bayer Ag | 5-acylamido-1-aryl-pyrazole |
| DE3636278A1 (de) | 1986-10-24 | 1988-05-05 | Hoechst Ag | Herbizide mittel auf der basis von cyclischen (alpha)-iminocarbon-saeureaniliden sowie neue (alpha)-iminocarbonsaeureanilide und verfahren zu ihrer herstellung |
| EP0507863A4 (en) | 1989-12-28 | 1993-07-07 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| WO1992009572A1 (en) | 1990-11-26 | 1992-06-11 | Taisho Pharmaceutical Co., Ltd. | Anilide derivative |
| US5362878A (en) | 1991-03-21 | 1994-11-08 | Pfizer Inc. | Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) |
| CA2077252C (en) | 1992-08-31 | 2001-04-10 | Khashayar Karimian | Methods of making ureas and guanidines, and intermediates therefor |
| IL107120A (en) | 1992-09-29 | 1997-09-30 | Boehringer Ingelheim Int | Atomising nozzle and filter and spray generating device |
| US5256658A (en) | 1993-01-15 | 1993-10-26 | Ortho Pharmaceutical Corporation | Angiotensin II inhibitors |
| US5428037A (en) | 1993-04-09 | 1995-06-27 | Syntex Pharmaceuticals, Ltd. | Heterocyclic derivatives in the treatment of Ischaemia and related diseases |
| DE4319039A1 (de) | 1993-06-08 | 1994-12-15 | Bayer Ag | Substituierte (2-Oxo-1-benzimidazolinyl)-piperidine, Verfahren zu ihrer Herstellung und Verwendung als anti-retrovirale Mittel |
| US5834490A (en) | 1993-11-04 | 1998-11-10 | Instituto De Investigacion Y Desarrolo Quimico Biologico, S.A. | Cyclopropyl derivatives, preparation method there-of and applications |
| US5583147A (en) | 1994-03-23 | 1996-12-10 | The Dupont Merck Pharmaceutical Company | Amides for the treatment of atherosclerosis |
| US5491170A (en) | 1994-12-19 | 1996-02-13 | Warner-Lambert Company | β-carboxy sulfonamide ACAT inhibitors |
| WO1996026925A1 (en) | 1995-03-01 | 1996-09-06 | Banyu Pharmaceutical Co., Ltd. | Arylthioacetamide derivatives |
| DE19536902A1 (de) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
| DE19536903C2 (de) | 1995-10-04 | 1998-09-10 | Boehringer Ingelheim Int | Vorrichtung zum Haltern eines fluidischen Bauteils |
| DE19545226C1 (de) | 1995-12-05 | 1997-06-19 | Boehringer Ingelheim Int | Sperrspannwerk für einen federbetätigten Abtrieb |
| CA2257206A1 (en) | 1996-06-07 | 1997-12-11 | Gui-Bai Liang | Oxadiazole benzenesulfonamides as selective .beta.3 agonists for the treatment of diabetes and obesity |
| US5808453A (en) | 1996-08-21 | 1998-09-15 | Siliconix Incorporated | Synchronous current sharing pulse width modulator |
| CA2264666A1 (en) | 1996-09-13 | 1998-03-19 | Schering Corporation | Substituted benzocycloheptapyridine useful as inhibitors of farnesyl-protein transferase |
| WO1998013340A1 (en) | 1996-09-27 | 1998-04-02 | Pharmacia & Upjohn Company | β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS |
| US5968929A (en) | 1996-10-30 | 1999-10-19 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| US6048900A (en) | 1998-02-13 | 2000-04-11 | Bayer Corporation | Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists |
| TR199902012T2 (xx) | 1997-02-21 | 2000-01-21 | Bayer Aktiengesellschaft | Arils�lfonamidler ve analoglar� |
| PT973512E (pt) | 1997-02-27 | 2004-07-30 | Wyeth Corp | N-hidroxi-2-(alquil, aril ou heteroaril sulfanil, sulfinilou sulfonil)-alquil, aril ou heteroarilamidas substituidas na posicao 3 como inibidores de metaloproteinases da matriz |
| US5958940A (en) | 1997-09-11 | 1999-09-28 | Schering Corporation | Tricyclic compounds useful as inhibitors of farnesyl-protein transferase |
| IL135586A0 (en) | 1997-11-21 | 2001-05-20 | Upjohn Co | α-HYDROXY, -AMINO, AND HALO DERIVATIVES OF β-SULFONYL HYDROXAMIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| US6359009B1 (en) | 1998-04-08 | 2002-03-19 | Basf Aktiengesellschaft | Substituted anilide insecticidal agents |
| GB9810671D0 (en) | 1998-05-18 | 1998-07-15 | Pfizer Ltd | Anti-pruritic agents |
| US6756404B2 (en) | 1998-06-18 | 2004-06-29 | The Research & Development Institute, Inc. | Autoinducer compounds |
| US6337347B1 (en) | 1998-06-18 | 2002-01-08 | The Research & Development Institute, Inc. | Autoinducer compounds |
| CA2339018A1 (en) | 1998-08-07 | 2000-02-17 | Applied Research Systems Ars Holding N.V. | Fsh mimetics for the treatment of infertility |
| CA2368631A1 (en) | 1999-03-26 | 2000-10-05 | Euro-Celtique S.A. | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
| DE19929076A1 (de) | 1999-06-25 | 2000-12-28 | Aventis Pharma Gmbh | Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| US6355653B1 (en) | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
| CA2387892A1 (en) | 1999-10-18 | 2001-04-26 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| AR035912A1 (es) | 2000-03-02 | 2004-07-28 | Aventis Cropscience Sa | Compuestos de 4-tiometilpirazol, composicion plaguicida, metodo para el control de plagas en un lugar, semillas tratadas o recubiertas,uso de estos compuestos o composiciones para el control de plagas, uso de estos compuestos para preparar un medicamento veterinario, y,proceso para la preparacion de |
| ES2344831T3 (es) | 2000-06-23 | 2010-09-08 | Mitsubishi Tanabe Pharma Corporation | Potenciadores de un efecto antitumoral. |
| IL156487A0 (en) | 2000-12-22 | 2004-01-04 | Astrazeneca Ab | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
| US20020099035A1 (en) | 2001-01-24 | 2002-07-25 | Sandanayaka Vincent P. | Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
| US7067539B2 (en) | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
| US7507767B2 (en) | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
| WO2002088089A1 (en) | 2001-04-19 | 2002-11-07 | Banyu Pharmaceutical Co., Ltd. | Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions |
| KR20050033043A (ko) | 2001-10-04 | 2005-04-08 | 노파르티스 아게 | 유기 화합물 |
| AU2002363250A1 (en) | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| JP2003155285A (ja) | 2001-11-19 | 2003-05-27 | Toray Ind Inc | 環状含窒素誘導体 |
| WO2003055482A1 (en) | 2001-12-21 | 2003-07-10 | Novo Nordisk A/S | Amide derivatives as gk activators |
| AU2003221298B2 (en) | 2002-03-05 | 2009-02-19 | Boehringer Ingelheim Animal Health USA Inc. | 5-substituted-alkylaminopyrazole derivatives as pesticides |
| MXPA04012704A (es) | 2002-06-19 | 2005-03-23 | Schering Corp | Agonistas de los receptores canabinoides. |
| AU2003264018A1 (en) | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| MXPA05001592A (es) | 2002-08-09 | 2005-05-05 | Astrazeneca Ab | Oxadiazoles como moduladores de receptor-5 de glutamato metabotropico. |
| UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| HRP20050053A2 (en) | 2002-09-19 | 2005-04-30 | Solvay Pharmaceuticals B.V. | 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands |
| GB0222495D0 (en) | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
| KR20050070046A (ko) | 2002-10-09 | 2005-07-05 | 화이자 프로덕츠 인크. | 퇴행성신경 장애 치료를 위한 티아졸 화합물 |
| AU2003284165B2 (en) | 2002-10-30 | 2008-12-11 | Merck Sharp & Dohme Corp. | Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity |
| US7642277B2 (en) | 2002-12-04 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
| SE0300010D0 (sv) | 2003-01-07 | 2003-01-07 | Astrazeneca Ab | Novel Compounds |
| US7718692B2 (en) | 2004-02-13 | 2010-05-18 | Carson John R | Hetero-substituted acetanilide derivatives as analgesic agents |
| DE10307845A1 (de) | 2003-02-25 | 2004-09-02 | Bayer Cropscience Gmbh | Heterocyclische Amide, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| BRPI0409721A (pt) | 2003-05-12 | 2006-05-02 | Pfizer Prod Inc | compostos de isoxazol e isotiazol para o tratamento de distúrbios neurodegenerativos |
| JP2004337701A (ja) | 2003-05-14 | 2004-12-02 | Seiko Epson Corp | 液滴吐出方法、及び液滴吐出装置 |
| JP2007502828A (ja) | 2003-08-21 | 2007-02-15 | ファイザー・プロダクツ・インク | 神経変性性疾患の治療のための化合物 |
| WO2005068448A1 (en) | 2003-08-29 | 2005-07-28 | Ionix Pharmaceuticals Limited | Sulfonamides antagonising n-type calcium channels |
| CA2538291A1 (en) | 2003-09-18 | 2005-03-31 | Merck & Co., Inc. | Substituted sulfonamides |
| WO2005030127A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
| EP1678121A4 (en) | 2003-10-24 | 2007-07-25 | Exelixis Inc | MODULATORS OF TAO KINASES AND METHODS OF USE |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| JP4769082B2 (ja) | 2003-12-17 | 2011-09-07 | 武田薬品工業株式会社 | ウレア誘導体、その製造法及び用途 |
| WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| FR2866885B1 (fr) | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique |
| US20070185152A1 (en) | 2004-03-02 | 2007-08-09 | Smithkline Beecham Corporation | Inhibitors of akt activity |
| CN1934091B (zh) | 2004-03-23 | 2012-02-08 | 辉瑞产品公司 | 治疗神经变性障碍的咪唑化合物 |
| US7232820B2 (en) | 2004-04-01 | 2007-06-19 | Pfizer Inc | Thiadiazole-amine compounds for the treatment of neurodegenerative disorders |
| US8008020B2 (en) | 2004-06-03 | 2011-08-30 | Vermillion, Inc. | Biomarkers for peripheral artery disease |
| US20060009491A1 (en) | 2004-06-24 | 2006-01-12 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| US20050288338A1 (en) | 2004-06-24 | 2005-12-29 | Wenqing Yao | Amido compounds and their use as pharmaceuticals |
| WO2006000031A1 (en) | 2004-06-25 | 2006-01-05 | Cochlear Limited | Electrode assembly |
| FR2872813B1 (fr) | 2004-07-09 | 2007-01-19 | Sanofi Synthelabo | Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique |
| JP4882748B2 (ja) | 2004-09-16 | 2012-02-22 | アステラス製薬株式会社 | トリアゾール誘導体またはその塩 |
| WO2006044645A2 (en) | 2004-10-13 | 2006-04-27 | Adolor Corporation | Sulfamoyl benzamides and methods of their use |
| JP2006143667A (ja) | 2004-11-22 | 2006-06-08 | Ube Ind Ltd | ピペコリン酸アミド誘導体及び抗菌剤 |
| CN101115726A (zh) | 2004-12-03 | 2008-01-30 | 先灵公司 | 作为cb1拮抗剂的取代哌嗪 |
| EP2368881A1 (en) | 2005-01-10 | 2011-09-28 | University of Connecticut | Heteropyrazole analogs acting on cannabinoid receptors |
| EP1846364A1 (en) | 2005-01-25 | 2007-10-24 | Universita' Degli Studi di Siena | New potent and selective ligands of cannabinoid receptors |
| GB0504753D0 (en) | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| GB0506133D0 (en) | 2005-03-24 | 2005-05-04 | Sterix Ltd | Compound |
| FR2885364B1 (fr) | 2005-05-03 | 2007-06-29 | Sanofi Aventis Sa | Derives d'alkyl-, alkenyl-et alkynylcarbamates, leur preparation et leur application en therapeutique |
| WO2007020502A2 (en) | 2005-08-16 | 2007-02-22 | Pharmacia & Upjohn Company Llc | Cannabinoid receptor ligands and uses thereof |
| JP4234786B1 (ja) | 2005-11-08 | 2009-03-04 | ファイザー・リミテッド | ピラゾール誘導体およびその医学的使用 |
| CA2632030A1 (en) | 2005-12-15 | 2007-06-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| JP2009523161A (ja) | 2006-01-11 | 2009-06-18 | アストラゼネカ アクチボラグ | モルホリノピリミジン誘導体と療法におけるその使用 |
| WO2007101270A1 (en) | 2006-03-02 | 2007-09-07 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| EP1994011B1 (en) | 2006-03-06 | 2010-10-13 | RaQualia Pharma Inc | Sulfonyl benzimidazole derivatives |
| JP2009536613A (ja) | 2006-04-07 | 2009-10-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節する化合物 |
| CN101454302A (zh) | 2006-05-31 | 2009-06-10 | 艾博特公司 | 用作大麻素受体配位体的噻唑化合物及其用途 |
| EP2081905B1 (en) | 2006-07-28 | 2012-09-12 | Boehringer Ingelheim International GmbH | Sulfonyl compounds which modulate the cb2 receptor |
| MX2009002046A (es) | 2006-08-24 | 2009-03-06 | Astrazeneca Ab | Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos. |
| CA2664310A1 (en) | 2006-09-25 | 2008-04-03 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| WO2008048914A1 (en) | 2006-10-17 | 2008-04-24 | Boehringer Ingelheim International Gmbh | Polycyclic compounds which modulate the cb2 receptor |
| WO2008064054A2 (en) | 2006-11-21 | 2008-05-29 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| WO2008098025A1 (en) | 2007-02-08 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Arylsulfonamide compounds which modulate the cb2 receptor |
| JP5491871B2 (ja) | 2007-02-28 | 2014-05-14 | アドビナス セラピュティックス プライベート リミテッド | グルコキナーゼ活性化因子としての２，２，２−三置換アセトアミド誘導体、その方法及び薬学的応用 |
| EP2215080A1 (en) | 2007-10-25 | 2010-08-11 | Boehringer Ingelheim International GmbH | Diazepane compounds which modulate the cb2 receptor |
| JP5492092B2 (ja) | 2007-11-07 | 2014-05-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節する化合物 |
| EP2234984B1 (en) | 2007-12-17 | 2016-03-16 | Janssen Pharmaceutica, N.V. | Fluoroalkyl substituted benzimidazole cannabinoid agonists |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| EP2265585B1 (en) | 2008-02-21 | 2014-09-17 | Boehringer Ingelheim International GmbH | Amine and ether compounds which modulate the cb2 receptor |
| EP2418207A1 (en) | 2008-05-13 | 2012-02-15 | Boehringer Ingelheim International GmbH | Sulfone compounds which modulate the CB2 receptor |
| EP2326629B1 (en) | 2008-07-10 | 2013-10-02 | Boehringer Ingelheim International GmbH | Sulfone compounds which modulate the cb2 receptor |
| WO2010036630A2 (en) * | 2008-09-25 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the cb2 receptor |
| US8629157B2 (en) | 2009-01-05 | 2014-01-14 | Boehringer Ingelheim International Gmbh | Pyrrolidine compounds which modulate the CB2 receptor |
| WO2010096371A2 (en) | 2009-02-18 | 2010-08-26 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds which modulate the cb2 receptor |
| US8299103B2 (en) * | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| JP5756800B2 (ja) | 2009-06-16 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体 |
| US20120277296A1 (en) | 2009-07-23 | 2012-11-01 | Sophie Lotersztajn | Selective CB2 Receptor Agonists for Use in the Prevention or Treatment of Alcoholic Liver Disease |
| CA2770866C (en) | 2009-08-28 | 2017-10-10 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| CA2771710A1 (en) | 2009-09-18 | 2011-03-24 | Zalicus Pharmaceuticals Ltd. | Aryl sulphone derivatives as calcium channel blockers |
| JP2013505295A (ja) | 2009-09-22 | 2013-02-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を選択的に調節する化合物 |
| US9315454B2 (en) | 2010-01-15 | 2016-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
| EP2542539B1 (en) | 2010-03-05 | 2014-02-26 | Boehringer Ingelheim International GmbH | Tetrazole compounds which selectively modulate the cb2 receptor |
| JP5746764B2 (ja) | 2010-07-22 | 2015-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節する化合物 |
| EP2803668A1 (en) * | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
-
2013
- 2013-05-17 EP EP13168165.2A patent/EP2803668A1/en not_active Ceased
-
2014
- 2014-05-15 US US14/278,064 patent/US8865744B1/en active Active
- 2014-05-16 CN CN201480028629.5A patent/CN105229000B/zh active Active
- 2014-05-16 NZ NZ713614A patent/NZ713614A/en unknown
- 2014-05-16 EP EP14728849.2A patent/EP2997027B1/en active Active
- 2014-05-16 ES ES14728849.2T patent/ES2626396T3/es active Active
- 2014-05-16 KR KR1020157032851A patent/KR102293386B1/ko active Active
- 2014-05-16 MX MX2015015665A patent/MX350885B/es active IP Right Grant
- 2014-05-16 UA UAA201512357A patent/UA118031C2/uk unknown
- 2014-05-16 EA EA201501123A patent/EA031021B1/ru unknown
- 2014-05-16 UY UY0001035571A patent/UY35571A/es unknown
- 2014-05-16 PT PT147288492T patent/PT2997027T/pt unknown
- 2014-05-16 CA CA2912463A patent/CA2912463C/en active Active
- 2014-05-16 BR BR112015028235A patent/BR112015028235A2/pt not_active Application Discontinuation
- 2014-05-16 DK DK14728849.2T patent/DK2997027T3/en active
- 2014-05-16 PL PL14728849T patent/PL2997027T3/pl unknown
- 2014-05-16 JP JP2016513374A patent/JP6309616B2/ja active Active
- 2014-05-16 TW TW103117398A patent/TW201536762A/zh unknown
- 2014-05-16 US US14/891,051 patent/US9650370B2/en active Active
- 2014-05-16 AU AU2014267197A patent/AU2014267197B2/en active Active
- 2014-05-16 WO PCT/EP2014/060033 patent/WO2014184327A1/en not_active Ceased
- 2014-05-16 AR ARP140101980A patent/AR096338A1/es unknown
-
2015
- 2015-10-26 ZA ZA2015/07957A patent/ZA201507957B/en unknown
- 2015-10-27 IL IL242309A patent/IL242309B/en active IP Right Grant
- 2015-11-04 PH PH12015502523A patent/PH12015502523A1/en unknown
- 2015-11-09 CL CL2015003286A patent/CL2015003286A1/es unknown
-
2017
- 2017-04-19 US US15/491,035 patent/US10112934B2/en active Active
-
2018
- 2018-09-27 US US16/143,523 patent/US10570125B2/en active Active
-
2020
- 2020-01-22 US US16/749,412 patent/US11084810B2/en active Active
-
2021
- 2021-08-10 US US17/398,155 patent/US11725004B2/en active Active
-
2023
- 2023-06-30 US US18/216,669 patent/US12344601B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102293386B1 (ko) | 신규한 (시아노-디메틸-메틸)-이속사졸 및 -[1,3,4]티아디아졸 | |
| DK2997021T3 (en) | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | |
| JP6641367B2 (ja) | ソマトスタチン受容体サブタイプ４（ｓｓｔｒ４）アゴニストとしてのモルホリンおよび１，４−オキサゼパンアミド | |
| JP6590927B2 (ja) | ソマトスタチン受容体サブタイプ４（ｓｓｔｒ４）作動薬としてのアリール及びヘテロアリール縮合テトラヒドロ−１，４−オキサゼピンアミド | |
| HK1222851B (en) | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20151117 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20170629 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20190515 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20201126 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20210521 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20210819 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20210820 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |